Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Cardiotoxicity in a dish: new insights for personalized therapy

A recent study identifies differences in human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes from patients with breast cancer who were treated with doxorubicin and either did or did not develop cardiotoxicity. The results open up new avenues for the development of personalized therapy and the prevention of cardiotoxicity.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Cardiac hiPSCs can give indications as to the cardiotoxicity of doxorubicin.

Kim Caesar/Nature Publishing Group


  1. Ewer, M.S. & Ewer, S.M. Nat. Rev. Cardiol. 12, 547–558 (2015).

    CAS  Article  Google Scholar 

  2. Burridge, P.W. et al. Nat. Med. 22, 547–556 (2016).

    CAS  Article  Google Scholar 

  3. Burridge, P.W. et al. Nat. Methods 11, 855–860 (2014).

    CAS  Article  Google Scholar 

  4. Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Timothy J Kamp.

Ethics declarations

Competing interests

T.J.K. is a consultant for Cellular Dynamics International.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Biermann, M., Kamp, T. Cardiotoxicity in a dish: new insights for personalized therapy. Nat Med 22, 459–460 (2016).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer